The Valley Desk

Clinical trial reportBreast cancer research and treatmentPublished

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Breast cancer research and treatment
Published
Subject terms
Humans; Breast Neoplasms; Neoplasm Metastasis; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome; Double-Blind Method; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Bevacizumab
PubMed ID
38967884
PubMed Central ID
PMC11297090
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal